News | March 12, 2022
Terran Biosciences acquires Concert’s CNS therapeutics portfolio
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Paves way for CNS cancer test rollout
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
Subscribe To Our Newsletter & Stay Updated
